美国 · SEC FORM 4
ZEVRA THERAPEUTICS, INC.
ZVRA · Nasdaq · CIK 0001434647 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
8 同一窗口内观察到的 Form 4 交易行
5 sales · 3 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-09-12 · FAVORITO TAMARA A.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 7,147,220
- 上期报告
- 5,738,663
- 日均成交量
- 998,161
- 回补天数
- 7.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-09-12 | FAVORITO TAMARA A | 买入 (P) | Common Stock | 3,175 | USD 7.79 | USD 24,733 | SEC 申报 ↗ |
| 2025-09-12 | Shih Alvin | 买入 (P) | Common Stock | 20,000 | USD 7.89 | USD 157,800 | SEC 申报 ↗ |
| 2025-08-19 | Bode John B | 买入 (P) | Common Stock | 5,000 | USD 9.17 | USD 45,850 | SEC 申报 ↗ |
| 2025-03-28 | Watton Corey Michael | 买入 (P) | Common Stock | 300 | USD 7.84 | USD 2,352 | SEC 申报 ↗ |
| 2025-03-19 | Bode John B | 买入 (P) | Common Stock | 10,000 | USD 7.96 | USD 79,600 | SEC 申报 ↗ |
| 2024-10-11 | Watton Corey Michael | 买入 (P) | Common Stock | 500 | USD 7.92 | USD 3,960 | SEC 申报 ↗ |
| 2024-07-17 | Clifton R. LaDuane | 买入 (P) | Common Stock | 2,000 | USD 6.77 | USD 13,540 | SEC 申报 ↗ |
| 2024-07-16 | Anderson Thomas | 买入 (P) | Common Stock | 10,000 | USD 6.81 | USD 68,100 | SEC 申报 ↗ |
| 2024-07-12 | Bode John B | 买入 (P) | Common Stock | 10,000 | USD 5.87 | USD 58,700 | SEC 申报 ↗ |
| 2023-09-06 | Clifton R. LaDuane | 买入 (P) | Common Stock | 1,000 | USD 4.96 | USD 4,960 | SEC 申报 ↗ |
| 2023-09-06 | Anderson Thomas | 买入 (P) | Common Stock | 10,000 | USD 4.88 | USD 48,800 | SEC 申报 ↗ |
| 2023-09-05 | Schafer Joshua | 买入 (P) | Common Stock | 500 | USD 5.13 | USD 2,565 | SEC 申报 ↗ |
| 2023-09-05 | Bode John B | 买入 (P) | Common Stock | 10,000 | USD 5.13 | USD 51,300 | SEC 申报 ↗ |
| 2023-06-23 | Watton Corey Michael | 买入 (P) | Common Stock | 275 | USD 5.95 | USD 1,636 | SEC 申报 ↗ |
| 2023-06-09 | Watton Corey Michael | 买入 (P) | Common Stock | 325 | USD 5.52 | USD 1,794 | SEC 申报 ↗ |
Form 4 申报证据
28 transaction lines in the latest 365-day window; 135 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | McFarlane Neil F. | 卖出 (S) | Common Stock | 20,000 | USD 11.25 | USD 224,948 | SEC 申报 ↗ |
| 2026-10-10 | McFarlane Neil F. | 期权行权／转换 (M) | Common Stock | 50,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-14 | Thompson Rahsaan | 卖出 (S) | Common Stock | 42,666 | USD 11.13 | USD 474,873 | SEC 申报 ↗ |
展开近期 Form 4 证据 (27 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | McFarlane Neil F. | 卖出 (S) | Common Stock | 20,000 | USD 11.25 | USD 224,948 | SEC 申报 ↗ |
| 2026-10-10 | McFarlane Neil F. | 期权行权／转换 (M) | Common Stock | 50,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-14 | Thompson Rahsaan | 卖出 (S) | Common Stock | 42,666 | USD 11.13 | USD 474,873 | SEC 申报 ↗ |
| 2026-08-10 | Watton Corey Michael | 卖出 (S) | Common Stock | 12,300 | USD 11.25 | USD 138,375 | SEC 申报 ↗ |
| 2026-08-10 | Watton Corey Michael | 期权行权／转换 (M) | Common Stock | 12,300 | USD 4.97 | USD 61,131 | SEC 申报 ↗ |
| 2026-06-22 | Thompson Rahsaan | 卖出 (S) | Common Stock | 34,557 | USD 12.68 | USD 438,183 | SEC 申报 ↗ |
| 2026-06-21 | Thompson Rahsaan | 期权行权／转换 (M) | Common Stock | 66,667 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-11 | Thompson Rahsaan | 卖出 (S) | Common Stock | 1,794 | USD 11.30 | USD 20,272 | SEC 申报 ↗ |
| 2026-03-24 | Bode John B | 期权行权／转换 (M) | Common Stock | 78,400 | USD 4.93 | USD 386,512 | SEC 申报 ↗ |
| 2026-02-09 | McFarlane Neil F. | 卖出 (S) | Common Stock | 14,625 | USD 8.56 | USD 125,190 | SEC 申报 ↗ |
| 2026-02-07 | McFarlane Neil F. | 期权行权／转换 (M) | Common Stock | 37,500 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-03 | Schafer Joshua | 卖出 (S) | Common Stock | 10,500 | USD 9.19 | USD 96,495 | SEC 申报 ↗ |
| 2026-02-03 | Sangiovanni Timothy J. | 卖出 (S) | Common Stock | 3,000 | USD 9.18 | USD 27,540 | SEC 申报 ↗ |
| 2026-02-02 | McFarlane Neil F. | 卖出 (S) | Common Stock | 91,000 | USD 9.38 | USD 853,580 | SEC 申报 ↗ |
| 2026-01-31 | Schafer Joshua | 期权行权／转换 (M) | Common Stock | 35,334 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-31 | Sangiovanni Timothy J. | 期权行权／转换 (M) | Common Stock | 11,666 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-31 | McFarlane Neil F. | 期权行权／转换 (M) | Common Stock | 233,334 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-30 | Thompson Rahsaan | 卖出 (S) | Common Stock | 4,080 | USD 8.83 | USD 36,026 | SEC 申报 ↗ |
| 2026-01-30 | Thompson Rahsaan | 期权行权／转换 (M) | Common Stock | 11,333 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-30 | Schafer Joshua | 卖出 (S) | Common Stock | 3,375 | USD 8.83 | USD 29,801 | SEC 申报 ↗ |
| 2026-01-30 | Schafer Joshua | 期权行权／转换 (M) | Common Stock | 11,333 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-30 | Sangiovanni Timothy J. | 卖出 (S) | Common Stock | 1,750 | USD 8.82 | USD 15,435 | SEC 申报 ↗ |
| 2026-01-30 | Sangiovanni Timothy J. | 期权行权／转换 (M) | Common Stock | 6,333 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-30 | Quartel Adrian W | 卖出 (S) | Common Stock | 4,533 | USD 8.83 | USD 40,026 | SEC 申报 ↗ |
| 2026-01-30 | Quartel Adrian W | 期权行权／转换 (M) | Common Stock | 11,333 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-31 | Clifton R. LaDuane | 期权行权／转换 (M) | Common Stock | 140,667 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-31 | Clifton R. LaDuane | 代扣税 (F) | Common Stock | 48,513 | USD 8.96 | USD 434,676 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ZVRA |
| CIK | 0001434647 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 135 transaction lines from 2020-03-05 to 2026-10-12 88 P purchase lines · 20 S sale lines · 27 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.